CFO transition
Longeveron Inc. CFO transition: Marie Washburn to succeed Lisa Locklear
Longeveron Inc. reported in a Form 8-K filed July 6, 2026 that Marie Washburn will succeed Lisa Locklear as Senior Vice President and Chief Financial Officer, effective July 13, 2026.
In the filing's words
on June 30, 2026, the Company appointed Marie Washburn to the Company’s executive leadership team in the role of Senior Vice President and Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer of the Company, effective July 13, 2026 (the “Effective Date”).
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Longeveron Inc. (LGVN) |
|---|---|
| Event | Transition |
| Incoming | Marie Washburn |
| Outgoing | Lisa Locklear |
| Title in the filing | Senior Vice President and Chief Financial Officer |
| Effective | July 13, 2026 |
| 8-K filed | July 6, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Vice President and Corporate Controller, Longeveron Inc. |
| SEC CIK | 0001721484 |
Longeveron Inc. reported this change in a Form 8-K, Item 5.02, filed July 6, 2026. The filing's own words are quoted above.
Same industry, July 2026
7Other moves filed that month at companies the roster files under SIC “Pharmaceutical Preparations”.
3 months ago· 2026-07-31AppointmentGCAN
The Greater Cannabis Company, Inc. appoints Michelle Cervantes Vivanco as CFO
3 months ago· 2026-07-28TransitionVYNE
Yarrow Bioscience, Inc. CFO transition: Tyler Zeronda to succeed Mutya Harsch
3 months ago· 2026-07-22InterimKROS
Keros Therapeutics, Inc. names Annita Tanini interim CFO
3 months ago· 2026-07-20AppointmentPMHS
Polomar Health Services, Inc. appoints Douglas Beck as CFO
4 months ago· 2026-07-13AppointmentMBX
MBX Biosciences, Inc. appoints John Smither as CFO
4 months ago· 2026-07-08TransitionOVID
Ovid Therapeutics Inc. CFO transition: Charles Carter to succeed Jeffrey Rona
4 months ago· 2026-07-06AppointmentOGEN
Oragenics, Inc. appoints John Spencer as CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Marie Washburn? Send a correction with the primary source.